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Abstract
Genome-wide association studies have successfully identified over 70 loci associated with the risk of type 2 diabetes mellitus (T2DM) in multiple
populations of European ancestry. However, the risk attributable to an individual variant is modest and does not yet provide convincing evidence
for clinical utility. Association between these established genetic variants and T2DM in general populations is hitherto understudied in the isolated
populations, such as the Uyghurs, resident in Hetian, far southern Xinjiang Uyghur Autonomous Region, China. In this case–control study, we
genotyped 13 single-nucleotide polymorphisms (SNPs) at 10 genes associated with diabetes in 130 cases with T2DM and 135 healthy controls
of Uyghur, a Chinese minority ethnic group. Three of the 13 SNPs demonstrated significant association with T2DM in the Uyghur population.
There were significant differences between the T2DM patients and controls in the risk allele distributions of rs3792267 (CAPN10) (P = 0.002),
rs1501299 (APM1) (P = 0.017), and rs3760776 (FUT6) (P = 0.031). Allelic carriers of rs3792267-A, rs1501299-T, and rs3760776-T had a 2.24-
fold [OR (95% CI): 1.35–3.71], 0.59-fold [OR (95% CI): 0.39–0.91], 0.57-fold [OR (95% CI): 0.34–0.95] increased risk for T2DM respectively.
We further confirmed that the cumulative risk allelic scores calculated from the 13 susceptibility loci for T2DM differed significantly between the
T2DM patients and controls (P = 0.001), and the effect of obesity/overweight on T2DM was only observed in the subjects with a combined risk
allelic score under a value of 17. This study observed that the SNPs rs3792267 in CAPN10, rs1501299 in APM1, and rs3760776 in FUT6 might
serve as potential susceptible biomarkers for T2DM in Uyghurs. The cumulative risk allelic scores of multiple loci with modest individual effects
are also significant risk factors in Uyghurs for T2DM, particularly among non-obese individuals. This is the first investigation having observed/
found genetic variations on genetic loci functionally linked with glycosylation associated with the risk of T2DM in a Uyghur population.
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Introduction
As a common heterogeneous disease, type 2 diabetes mellitus
(T2DM) has become a global health catastrophe threatening econo-
mies especially in those of low- and middle-income countries in which
more than 80% of diabetes deaths occur [1]. It is estimated that the
number of people with diabetes worldwide will rise to 552 million in
the year of 2030 if no urgent action is taken, and meanwhile diabetes
will be the 7th leading cause of death [2, 3]. In China, 9.7% of Chinese
adults are suffering from T2DM, 60.7% of them are unaware, and
15.5% have pre-diabetes at risk of cardiovascular diseases [4]. T2DM
is characterized by two fundamental features: insulin resistance and
progressive pancreatic b-cell dysfunction, corresponding defects in
both insulin action and secretion respectively [5]. For the time being,
ample evidence suggests that T2DM origins with an interaction
between genetic (i.e., family history of diabetes) and environmental
determinants (i.e., low physical exercise, smoking, high fat intake).
Subsequent association studies on the role of genetic variants to pre-
dict T2DM in certain ethnic groups have produced conflicting results
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[6–10]. Thereby, it is imperative to explore and define population-
specific genetic and environmental risk factors, which will shed light
on the pathogenesis of T2DM.
Recently, the research of glycomics is becoming an important
focus in different fields of biology and medicine. N-linked oligosac-
charides of glycoproteins (N-glycans) based on individual background
variability and inherent sensitivity reflect the integrative effect of both
genetic and environmental factors on the individuals, so as to make
N-glycans promising disease biomarkers [11–14]. Italian National
Research Center has proved the application of serum N-glycan pro-
files, especially those of fucose-containing glycans, as sensitive sur-
rogate biomarker for the presence of diabetes and metabolic
syndrome [15]. Currently, except one report on N-Glycan profiling of
metabolic syndrome in Chinese Han population [16], there is no study
to link N-glycan profiles with these factors with diabetes from Chinese
ethnic minorities. Thereby, there might be differences in the contribu-
tion of known single-nucleotide polymorphisms (SNPs) associated
with fucosylation among various ethnic populations [17, 18].
In history, Xinjiang, in the northwestern frontier area of China,
served as the key controlling section of the well-known Silk Road,
which was an ancient network of trade and cultural transmission
routes that were central to cultural interaction through regions of the
Asian continent connecting the West and East by merchants, pilgrims,
monks, soldiers, nomads, and urban dwellers from China and India to
the Mediterranean Sea during various periods of time [19]. Conse-
quently, the ethnic minorities including Uyghurs in Xinjiang became
admixed populations with both eastern and western Eurasian ances-
tries [20]. However, as time goes on, the Uyghurs, living in Hetian,
far southern Xinjiang Uyghur Autonomous Region, have been practic-
ing consanguinity and endogamy since they settled down in the area
some 2000–2500 years (80–100 generations) ago, and are highly
distinguishable from both current Europeans and East Asians due to
the endogamy and genetic isolation in terms of the time scale of
historical events [20, 21]. Therefore, the Uyghurs are a classically
well-defined isolated population, practicing endogamy resident in a
relatively homogeneous environment and have large sib ships. And
they are overwhelmingly Muslim, and have their own language,
religious beliefs, and lifestyles that are very different from either Han
Chinese population or American/European populations [18, 22].
In the previous pilot study, we found that 16 T2DM-related SNPs
are of high level of variability and significant ethnic-specific differences
in Uyghur population compared with the other ethnic groups [18]. This
study aimed to further explore the possible association between 13
SNPs susceptibility loci and T2DM as well as the combined effects of
these loci on the susceptibility of T2DM in a Uyghur population.
Materials and methods
Study participants
Between April 2012 and July 2013, we recruited a total of 265 Uyghur
participants (130 T2DM patients and 135 healthy controls) from Hetian
of Xinjiang, China, where the Uyghur population was less affected by
the recent migration of Han Chinese. Both recruited cases and controls
were not directly biologically related, and in addition they had no inter-
marriage history with other ethnic groups within the latest three genera-
tions. All subjects underwent routine health check-ups at local Minfeng
Renmin Hospital in Hetian. Diagnosis of T2DM was made by physicians
according to 1999 World Health Organization (WHO) Criteria (fasting
plasma glucose greater than or equal to 7.0 mmol/l and/or 2-hrs
plasma glucose greater than or equal to 11.1 mmol/l) [23]. Biochemical
[fasting blood glucose (FBG), serum total cholesterol (TC), triglycerides
(TG), high-density lipoprotein cholesterol (HDL), and low-density
lipoprotein cholesterol (LDL)] and anthropometric measurements
[height, weight, body mass index (BMI)] were conducted as earlier
described [18]. Blood pressure was measured with a standard mercury
sphygmomanometer in a sitting position after at least a 5 min. rest.
Peripheral blood samples for analyses of biochemical indexes were col-
lected in ethylenediaminetetraacetic acid anti-coagulated tubes after an
overnight fast. The concentration of FBG was determined by the glucose
oxidase-peroxidase method using commercial kits. Total cholesterol
levels were analysed using cholesterol oxidase–peroxidase–amidopyrine
method, TG by glycerol phosphate oxidase–peroxidase–amidopyrine
method, HDL and LDL by enzymatic methods on a Hitachi 911 auto-
mated analyzer (Boehringer Mannheim, Mannheim, Germany).
All of the participants signed the informed consent before participa-
tion. This study was approved by the Ethical Committees of Xinjiang
University, Urumqi, China and Capital Medical University, Beijing, China.
Selection of the candidate SNPs
Thirteen SNPs [rs7754840 (CDKAL1), rs13266634 (SLC30A8),
rs4402960 (IGF2BP2), rs1501299 (APM1), rs2241766 (APM1),
rs2237892 (KCNQ1), rs2237895 (KCNQ1), rs35767 (IGF1), rs3792267
(CAPN10), rs10483776 (FUT8), rs7159888 (FUT8), rs3760776 (FUT6),
and rs7953249 (HNF1a)] were selected for the following reasons.
Firstly, we analysed nine SNPs from seven genes that had a nominal to
strong association with T2DM identified by genome-wide association
studies (GWAS) among populations of European or Asian ancestry, i.e.,
APM1, IGF1, CDKAL1, IGF2BP2, SLC30A8, KCNQ1, and CAPN10 [24].
CAPN10 gene has been identified as the first genetic locus susceptible
to T2DM by positional cloning in Finland [25]. In addition, four SNPs
[rs10483776 (FUT8), rs7159888 (FUT8), rs3760776 (FUT6), rs7953249
(HNF1a)] were selected based on their associations with plasma fucosy-
lation status [26]. Although more and more susceptibility loci for T2DM
are being identified, such glycosylation linked foundational loci have not
yet been examined up to date. Minor allele frequencies (MAF) of all
selected SNPs are more than 0.05 in both HapMap CEU data and Hap-
Map CHB data (http://hapmap.ncbi.nlm.nih.gov/).
SNPs genotyping
Genomic DNA was isolated from 200 ll venous blood samples using
QIAamp DNA Blood Mini Kit according to the manual instructions (Qiagen
Inc., Hilden, Germany). The concentration and purity of the isolated DNA
were measured using the Thermo Scientific NanoDrop 2000 spectropho-
tometer according to the manufacturer. The DNA samples were genotyped
by using Sequenom MassARRAY iPLEX Platform (Sequenom Inc., San
Diego, CA, USA) [18]. The PCR was executed in a 5 ll volume containing
1.8 ll deionized H2O, 0.5 ll 109 PCR buffer, 0.4 ll 25 mM MgCl2,
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0.1 ll of 25 mM dNTP mix, 1 ll 0.5 lM primer mix, 0.2 ll (1 U) of PCR
Hotstar enzyme, and 1 ll sample DNA. The PCR was performed in an ABI
GeneAmp PCR system 9700 thermal cycler (384 dual) with the following
conditions: denaturation at 95°C for 2 min. followed by 45 cyclers of
95°C for 30 sec., 56°C for 30 sec., 72°C for 1 min., followed by 72°C for
5 min. After each sample amplification, the PCR products were passed
through a cocktail of 1.53 ll H2O, 0.17 ll of 109 shrimp alkaline phos-
phatase (SAP) buffer, 0.3 ll (0.5 U) of SAP (Sequenom Inc.). This was
incubated 40 min. at 37°C, followed by 5 min. at 85°C and afterwards at
4°C for short-term storage of the reaction. The single base extension
reaction contained 0.619 ll H2O, 0.2 ll of 109 iPLEX
 Gold buffer,
0.2 ll of iPLEX Termination mix, 0.94 ll of primer mix (Sequenom
Inc.), 0.041 ll of iPLEX enzyme, and 7 ll SAP treated PCR products.
The single base extension reaction was performed in an ABI GeneAmp
PCR system 9700 thermal cycler (384 dual) with the following conditions:
denaturation at 94°C for 30 sec. followed by 40 cyclers of 94°C for
5 sec., 52°C for 5 sec., 80°C for 5 sec., 52°C for 5 sec., 80°C for 5 sec.,
52°C for 5 sec., 80°C for 5 sec., 52°C for 5 sec., 80°C for 5 sec., 52°C
for 5 sec., 80°C for 5 sec., followed by 72°C for 3 min. A total of 16 ll
molecular grade water and 6 mg clean resin (Sequenom Inc.) was added
to each sample. Sample plates were rotated on a rotator for approximately
35 min. and centrifuged at 3200 g for 3 min. The single base extension
reaction products were spotted onto a SpectroCHIP array (Sequenom
Inc.) using MassARRAY nanodispenser RS1000 (Sequenom Inc.). Then
matrix-assisted laser desorption/ionization time-of-flight mass spectrom-
etry was performed and results were visualized on the MassARRAY
compact system (Sequenom Inc.) using autorun settings. The three point
calibration generated was at the m/z = 5044.4, 8486.6, 9977.0 D for the
spectral analysis of all SNPs. The genotype call rate for each SNP
exceeded 95% for both T2DM patients and healthy controls.
Statistical analysis
All continuous variables were expressed as the mean  S.D. Normality
of distribution of all continuous variables was verified using the Kol-
mogorov–Smirnov tests. Continuous variables between T2DM and con-
trol groups were compared by Student’s t-test or rank sum test
according to the results of Normality tests. Hardy–Weinberg equilibrium
(HWE) for genotype frequencies was tested in both groups using chi-
squared test. P ≥ 0.05 was considered to obey the HWE. We consid-
ered the dominant and recessive genetic models in which the genotype
was assigned as 0 or 1, depending on whether subjects carried the
minor allele (genotype 1 for minor allele carrier, 0 for not, under domi-
nant model; genotype 1 for homozygous for minor allele, 0 for not,
under recessive model) [27]. Allelic frequencies in T2DM patients and
controls were compared by chi-squared test, and logistic regression
analyses were applied to evaluate differences in genotype distributions.
Odds ratios (ORs) were calculated after adjustment for age, gender and
BMI. In addition, to evaluate the combined effects of the SNPs, the
cumulative risk allelic scores were calculated, based on the results of
association analysis of candidate SNPs for T2DM. In such cases, we
considered an additive genetic model for each SNP, and assigned a
score of 0, 1, or 2 to the genotypes for the 13 loci, depending on
whether subjects carried the wild-type allele or were heterozygous or
homozygous for the risk allele [18]. The count method assumed that
each risk allele contributes equally and independently to the risk for
T2DM. The scores were modelled as a continuous variable and catego-
rized into quartiles. The effects of cumulative risk allelic scores, obesity/
overweight, and the interaction between the cumulative number of risk
alleles and obesity/overweight on the risk of T2DM were tested using
multivariate logistic regression. A two-sided P < 0.05 was considered
statistically significant.
The statistical analysis was conducted using SPSS for Windows, ver-
sion 17.0 (SPSS Inc., Chicago, IL, USA). Power calculations were per-
formed under current sample size and MAF observed in this study
using Quanto software version 1.2.4 (http://hydra.usc.edu/gxe).
Results
Sample characteristics
The demographic and clinical profiles of 265 Uyghur participants
(130 T2DM patients versus 135 healthy controls) are presented in
Table 1. The T2DM patients had significantly higher levels of BMI,
SBP, DBP, TC, TG, LDL and FBG compared to the controls
(P < 0.05). Significant difference was found neither in gender, nor in
HDL between the T2DM patients and healthy controls.
Association analysis of candidate SNPs for T2DM
A representative mass spectrum for SNP genotyping was shown in
Figure 1, and the assay information (i.e. homogeneous versus
heterozygous SNPs) was initially assessed by call cluster plot analy-
sis. The distributions of allelic and genotype frequencies of these 13
SNPs among the T2DM patients and controls, and the results from
the logistic regression analysis are given in Tables 2 and 3. The distri-
butions of allelic frequencies of the 11 SNPs conformed to HWE in
both cases and controls (P > 0.05), except those of the rs2241766
and rs7159888 (P < 0.05) in the T2DM patients. The MAF of these
SNPs were ranging from 0.11 to 0.52.
Allelic frequencies of three SNPs [rs3792267 (CAPN10), rs1501299
(APM1), and rs3760776 (FUT6)] were significantly different between
the T2DM and controls (P < 0.05). For rs3792267 (CAPN10), fre-
quency of the A allele was significantly higher in T2DM patients than
that in control group (0.20 versus 0.11, P = 0.004). For rs1501299
(APM1), frequency of the T allele was significantly lower in T2DM
patients than that in control group (0.19 versus 0.27, P = 0.028). For
rs3760776 (FUT6), frequency of the T allele was lower in T2DM patients
than that in controls, although did not show the statistical significance
(0.11 versus 0.17, P = 0.071). Multiple logistic regression analysis
(adjusted for age, gender and BMI) identified that participants with the
A allele for rs3792267 (CAPN10) had a 2.24-fold [OR (95% CI): 1.35–
3.71, P = 0.002] risk of T2DM compared with the G allele. The T alleles
at rs1501299 (APM1) and rs3760776 (FUT6) were also found to be sig-
nificantly associated with T2DM in logistic regression analysis [OR
(95% CI): 0.59 (0.39–0.91), P = 0.017 versus OR (95% CI): 0.57
(0.34–0.95), P = 0.031] (Table 2). For rs35767 (IGF1), frequency of
the T allele was significantly higher in T2DM patients than that in con-
trols (0.28 versus 0.20, P = 0.029), although did not show the statisti-
cal significance after age, gender and BMI adjusted [OR (95% CI): 1.48
(10.98–2.23, P = 0.062)] (Table 2). Contrary to SNP rs3792267/GG,
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Table 1 Demographic characteristics and biochemical measures of the study participants
T2DM (n = 130) Control (n = 135) P-value
Age (years) 58.60  11.15 56.36  16.81 0.200
Gender (male) 59 (45.4%) 52 (38.5%) 0.258
BMI (kg/m2) 25.49  3.51 24.08  3.61 0.001
SBP (mmHg) 134.19  18.54 120.41  13.13 <0.001
DBP (mmHg) 90.50  13.42 80.42  9.31 <0.001
TC (mmol/l) 4.99  0.99 4.01  1.16 <0.001
TG (mmol/l) 1.88  0.87 1.53  0.70 0.001
HDL (mmol/l) 1.24  0.30 1.24  0.27 0.979
LDL (mmol/l) 2.83  0.90 2.38  0.76 <0.001
FBG (mmol/l) 8.78  2.42 5.33  0.66 <0.001
Data are shown as mean  S.D. The P-values with statistical significance are indicated in bold numbers. SBP: systolic blood pressure;
DBP: diastolic blood pressure; TC: Total cholesterol; TG: Triglycerides; BMI: body mass index; FBG: fasting blood glucose.
Fig. 1Matrix-assisted laser desorption/ionization time-of-flight single-nucleotide polymorphism mass spectrum and call cluster plot.
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SNPs rs1501299/GG and rs3760776/CC were more frequent in the
T2DM group compared to the controls (63.1% versus 80%; 65.4% ver-
sus 51.1%; 78.5% versus 69.6%, respectively; Table 3).
To evaluate the combined effects of these 13 associated variants,
we calculated the cumulative risk allelic scores of these 13 risk alleles
that each participant had using a simple count approach. The average
of cumulative risk allelic scores of T2DM patients (15.15  2.19)
was significantly higher than that in controls (14.16  2.22)
(P = 0.001, t-test). Multivariable logistic regression analyses also
indicated that risk allelic scores were important factors of T2DM in
Uyhgur participants (P = 0.001).
To further examine the association between obesity/overweight and
T2DM across four categories of risk allelic scores, i.e., quartile 1 (Q1)
(risk allelic scores less than or equal to a value of 14), quartile2 (Q2)
(risk allelic scores equal to a value of 15 or 16), quartile 3 (Q3) (risk
allelic scores equal to a value of 17 or 18) and quartile 4 (Q4) (risk alle-
lic scores greater than or equal to a value of 19), we stratified the sub-
jects into two groups: the obese/overweight group (BMI ≥24 kg/m2)
and the non-obese group (BMI <24 kg/m2). Obesity/overweight was a
strong predictor of T2DM in the Uyghur participants (P = 0.004). How-
ever, obesity/overweight was not shown as a significant risk factor for
T2DM (P > 0.05) for the subjects in the Q3 and Q4 groups (Table 4).
Discussion
Genome-wide association studies have successfully identified over 70
loci associated with the risk of T2DM in multiple populations, espe-
cially in populations of European ancestry [28]. However, the risk
attributable to an individual variant to date is modest and does not yet
provide convincing evidence for clinical utility. Genetic studies have
revealed that different populations have different genetic structures
because of their complex demographic histories [29]. In addition, the
heterogeneity of drug responses further illustrates the genetic vari-
ants vary substantially among different Chinese ethnic groups [22].
Therefore, current available data are not likely to be applicable to all
populations. Uyghur is a classically well-defined isolated population,
practicing endogamy resident in a relatively homogeneous environ-
ment and having large sibships. Therefore, it would be an ideal popu-
lation for the study of genetic susceptibility.
Study findings
In this population-based case–control study, we extended the support
for T2DM candidate loci identified by GWAS [24] and revealed that
Table 2 Individual effects of the 13 candidate SNPs for T2DM in the Uyghur participants
Locus dbSNP A/a
T2DM Control Chi-square test
Logistic regression analysis
(adjusted for age, gender
and BMI)
Fminor PHWE Fminor PHWE P-value OR (95% CI) P-value
CAPN10 rs3792267 G*/A 0.20 0.90 0.11 0.69 0.004 2.24 (1.35–3.71) 0.002
APM1 rs1501299 G*/T 0.19 0.84 0.27 0.44 0.028 0.59 (0.39–0.91) 0.017
FUT6 rs3760776 C*/T 0.11 0.82 0.17 0.51 0.071 0.57 (0.34–0.95) 0.031
IGF1 rs35767 C/T* 0.28 0.91 0.20 0.39 0.029 1.48 (0.98–2.23) 0.062
KCNQ1 rs2237892 C*/T 0.18 0.51 0.17 0.63 0.753 1.05 (0.66–1.67) 0.841
KCNQ1 rs2237895 A/C* 0.36 0.60 0.39 0.19 0.458 0.85 (0.59–1.22) 0.381
APM 1 rs2241766 T/G* 0.20 0.004 0.22 0.51 0.606 0.94 (0.61–1.44) 0.780
IGF2BP2 rs4402960 G/T* 0.31 0.17 0.25 0.53 0.140 1.26 (0.85–1.87) 0.243
SLC30A8 rs13266634 C*/T 0.28 0.74 0.26 0.77 0.645 1.11 (0.75–1.64) 0.617
CDKAL1 rs7754840 G/C* 0.38 0.64 0.32 0.19 0.122 1.29 (0.89–1.88) 0.171
FUT8 rs10483776 A*/G 0.14 0.78 0.15 0.51 0.681 0.86 (0.52–1.42) 0.548
FUT8 rs7159888 A*/G 0.35 0.02 0.40 0.89 0.235 0.81 (0.56–1.16) 0.246
HNF1a rs7953249 G/A* 0.52 0.91 0.47 0.31 0.191 1.26 (0.88–1.79) 0.203
*Risk allele. A/a: major allele/minor allele. The P-values with statistical significance are indicated in bold numbers. PHWE: P-value of Hardy–Wein-
berg equilibrium test; Fminor: minor allele frequency; CAPN10: calpain 10; APM1: aminopeptidase M1; FUT6: fucosyltransferase 6; IGF1: insulin-
like growth factor 1; KCNQ1: potassium voltage-gated channel, subfamily Q, member 1; IGF2BP2: insulin-like growth factor 2 mRNA binding
protein 2; SLC30A8: solute carrier family 30 member 8; CDKAL1: cyclin-dependent kinase 5 regulatory subunit associated protein 1–like 1;
FUT8: fucosyltransferase 8; HNF1a: hepatocyte nuclear factor 1, alpha.
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Table 3 Frequencies of the genotypes of rs3792267 (CAPN10), rs1501299 (APM1) and rs3760776 (FUT6) in T2DM patients and controls
SNP Genotype T2DM no. (%) Control no. (%) P*
Logistic regression analysis (adjusted for age, gender
and BMI)†
Dominant Recessive
P OR (95% CI) P OR (95% CI)
rs3792267 (CAPN10) GG 82 (63.1%) 108 (80%) 0.006 0.002 2.51 (1.42–4.46) 0.204 2.55 (0.60–10.82)
GA 42 (32.3%) 25 (18.5%)
AA 5 (3.8%) 2 (1.5%)
rs1501299 (APM1) GG 85 (65.4) 69 (51.1) 0.034 0.009 0.51 (0.31–0.85) 0.732 0.91 (0.54–1.53)
GT 39 (30) 56 (41.5)
TT 5 (3.8) 8 (5.9)
rs3760776 (FUT6) CC 102 (78.5) 94 (69.6) 0.113 0.049 0.56 (0.31–0.99) 0.211 0.33 (0.06–1.86)
CT 26 (20) 36 (26.7)
TT 2 (1.5) 5 (3.7)
*The P-values for comparison of statistically difference among the three genotypes for certain SNP between T2DM and control subjects. †The
logistic regression model was used to obtain the odds ratios of the minor allele with the major allele as reference group. The P-values with sta-
tistical significance are indicated in bold numbers.
Table 4 Effect of obesity/overweight on T2DM according to quartiles of risk allelic scores
Quartiles of risk alleles T2DM (n = 130) Control (n = 135) OR* 95% CI P
All subject
Obese 82 62 2.075 1.263–3.407 0.004
Non-obese 48 73
Q1 (≤14)
Obese 28 33 2.158 1.002–4.647 0.049
Non-obese 19 43
Q2 (15, 16)
Obese 32 18 2.431 1.022–5.782 0.044
Non-obese 16 22
Q3 (17, 18)
Obese 18 10 0.667 0.150–2.973 0.595
Non-obese 9 4
Q4 (≥19)
Obese 4 1 4.978 0.306–81.083 0.26
Non-obese 4 4
*ORs and P-values on T2DM for obese/overweight and non-obese subjects were adjusted for age. The P-values with statistical significance are
indicated in bold numbers.
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the cumulative risk allelic scores that aggregate information from
multiple genetic variants are significant risk factors in the Uyghur
population. Among the 13 T2DM genetic susceptibility loci screened,
we found significant association with T2DM for three of them, i.e.,
rs3792267 (CAPN10), rs1501299 (APM1) and rs3760776 (FUT6).
CAPN10 gene, identified as the first susceptibility gene for T2DM
by positional cloning [25], has been associated the increased risk of
T2DM in different populations [30–32]. It has been well documented
that the abnormal expression of CAPN10 in pancreatic islets, muscle
and liver is related to insulin secretion and action, and thereby is con-
sidered to be an important novel pathway involved in glucose metabo-
lism [25]. Single-nucleotide polymorphism rs3792267polymorphism
in CAPN10 has been examined on the effect of regulating insulin sen-
sitivity and CAPN10 mRNA levels [33]. However, divergent results
were reported and gave a heterogeneous picture owing to racial or
regional differences [31, 32, 34, 35]. Our study revealed that the A
allele of rs3792267 of CAPN10 was significantly associated with
T2DM in Uyghur participants (P = 0.002, adjusted for age, gender
and BMI) (Table 2).
A significant association was detected between the A allele of
rs3792267 (CAPN10) and T2DM susceptibility in the dominant model
(P = 0.002; Table 3). Kommoju et al. showed that the increased A
allelic frequency of rs3792267 in the T2DM patients than that of con-
trols in a Indian population of Hyderabad [36], conferring the risk for
developing T2DM. Another study conducted on the Kurdish ethnic
group of Iran population also supported the association of A-allele of
rs3792267 with T2DM [10], which was consistent with the results of
this study for Uyghur participants. Furthermore, Li et al. also reported
association of the A allele with high risk of T2DM in Uyghur popula-
tion [6]. Yet, some studies showed two opposite trends of statistical
significance of the G- and A-allele towards T2DM in certain population
[34]. This discrepancy suggested that the association should be pop-
ulation-specific due to the differential allelic frequencies across differ-
ent human ethnic groups. The distribution of the ancestral G allele at
rs3792267 in controls reported in previous studies varied from 0.68
to 0.97 in different populations such as European [25, 37, 38], Arabic
[39], African-American [40], South Indian [41], Japanese [42] and
Chinese [43]. The frequency of the G allele for rs3792267 in Uyghur
controls (0.893) was reported to be similar level with African-Ameri-
cans, Tunisian Arab and South Indian, but higher than that in
Caucasian populations from Britain and Ireland, and lower than that in
Japanese. Uyghur, as one of typical Muslim minorities [44], has high
levels of consanguineous and/or endogamous marriage which might
increase the likelihood of presence of pathogenic mutations at a
higher homozygous level, with mean inbreeding coefficient of
0.0033–0.0065 [45]. Therefore, the accumulation of various
mutations due to endogamy seems to affect the distribution of allele
frequency across different population groups [18, 46, 47].
Among the other loci examined in this study, SNP rs1501299 in
APM1 also showed the significant association with T2DM in Uyghur
participants (P = 0.017, adjusted for age, gender and BMI, Table 2).
Single-nucleotide polymorphism rs1501299 locates in intron-2 within
the APM1 gene, which plays a pivotal role in regulating insulin sensitiv-
ity [48]. In this case–control study, the frequency of GG genotype of
rs1501299 was noted significantly higher in T2DM patients as
compared with that of controls, suggesting that the G allele may confer
increased risk for T2DM. Indeed, a significant association was detected
between the G allele of rs1501299 and T2DM susceptibility in the dom-
inant model (Table 3). Tu et al. reported that the rs1501299 polymor-
phism was associated with increased risk for T2DM, especially in
Chinese Han population [49]. The direction and magnitude of our result
were consistent with these previous reports [50, 51].
FUT6 gene, as a member of fucosyltransferase (FUT) family, is
involved in catalysing the inverting reaction, in which a fucose residue
is transferred from guanosine-diphosphate fucose (GDP-Fuc) to
molecules such as N-glycans [52]. Single-nucleotide polymorphism
rs3760776, in the promoter region of FUT6 [53], was also reported to
have association with plasma levels of fucosylated glycans such as
DG7 (P = 3.42 9 1012) and DG9 (P = 3.51 9 1017) [26]. In
mammals, fucose-containing glycans have been shown to be associ-
ated with the host-microbe interactions, transfusion reaction and
selectin-mediated leucocyte-endothelial adhesion [54, 55]. In our
case–control study, the frequency for the T allele in rs3760776 was
noted significantly lower in diabetic patients as compared with that of
controls (P = 0.031). In logistic regression analysis, marginal associ-
ation for SNP rs3760776 was detected in dominant model
(OR = 0.56, 95% CI: 0.31–0.99, P = 0.049) (Table 3). Single-nucleo-
tide polymorphism rs3760776 may affect the activity of FUT6
enzyme, and thus may alter individual’s capacity to fucose conversion
and in turn modify the risk in the development of T2DM. The study on
the glycosylation profiling of this same cohort of Uyghur T2DM
patients is currently under way in our laboratory to understand the
molecular mechanism underlying the statistically significant associa-
tions observed in this study.
Although significantly associated with T2DM, the risk attributable
to an individual variant is modest, which limits the clinical utility.
However, taken collectively, a combination of information from multi-
ple genetic variants may contribute substantially to the disease risk
and will be useful in characterizing population at high risk for T2DM.
We have shown that the cumulative risk allelic scores based on the
13 susceptible loci for T2DM are significant risk factors in the Uyghur
population samples (P = 0.001), consistent with several previous
studies in Asian populations [18, 56, 57]. In addition, our data sug-
gested that obesity/overweight is a strong predictor of T2DM
(P = 0.004), given obesity is associated with insulin resistance [58].
However, obesity/overweight was not shown as a significant risk fac-
tor of T2DM for the patients with the combined risk allelic scores
greater than or equal to the value of 17, perhaps due to the small
sample size in the subgroups, such as Q3 and Q4, with insufficient
statistical power. This result was comparable with the study among a
Japanese population [59], in which most T2DM patients were charac-
terized by a low BMI and shared the same pattern of genetic profiling
on the T2DM susceptible loci.
Study limitations
Our study has limitations. A relatively small sample size: the blood
sampling of minority groups was a very hard field-practice in the
remote areas of Xinjiang [18, 22]. Thereby, the combined data set
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provided statistical power of less than 80% (40.9–64.7%) to detect
SNPs with risk ratios greater than 1.5, given the significance level of
0.05. Thus, case–control studies with large samples and multiple
comparisons are required to confirm the effect of those SNPs on the
T2DM risk based on this current observation. Moreover, GWAS iden-
tify SNPs and other DNA variants associated with a disease, but can-
not on their own specify which genes are causal [60, 61]. Thereby,
function studies in carefully selected study participants and animal
model are also needed to specify the molecular mechanism underly-
ing the statistical association observed.
Conclusion
The SNP rs3792267 in CAPN10, rs1501299 in APM1, and rs3760776
in FUT6 might serve as potential susceptibility loci for T2DM in
Uyghurs. The cumulative risk allelic scores of multiple loci with mod-
est individual effects are also significant risk predictors/factors in
Uyghurs for T2DM, particularly among non-obese individuals. This is
the first investigation having observed/found genetic variations on
genetic loci functionally linked with glycosylation associated with the
risk of T2DM in a Uyghur population.
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